Beta-3 Adrenergic Agonist Medications
The primary beta-3 adrenergic agonist medications available for clinical use are mirabegron and vibegron, both FDA-approved for the treatment of overactive bladder (OAB) 1, 2, 3.
Available Beta-3 Agonists
Mirabegron
- Most extensively studied beta-3 agonist with robust evidence from multiple Phase III trials 2
- Available dosing: 25 mg and 50 mg daily 1
- Demonstrated efficacy comparable to antimuscarinics with a more favorable adverse effect profile 2, 4
- Proven cardiovascular safety in high-risk patients 2, 5
- Particularly beneficial in elderly patients with multiple comorbidities 2
Vibegron
- Second beta-3 agonist approved for OAB treatment 6
- Newer agent with potentially greater receptor potency than mirabegron 5
- Increases bladder capacity and reduces urgency episodes and incontinence 6
Solabegron
- Mentioned in guidelines but not yet widely available for clinical use 7
- Under investigation for cardiovascular applications 5
Clinical Context and Usage
Beta-3 agonists work by relaxing the detrusor muscle during bladder filling, increasing bladder capacity and reducing urgency symptoms 3, 6, 8. The 2023 EAU guidelines and 2024 AUA/SUFU guidelines position these agents as second-line pharmacologic therapy for OAB, either as monotherapy or in combination with antimuscarinics 1, 2, 3.
Key Advantages Over Antimuscarinics:
- Lower discontinuation rates due to adverse effects 2, 4
- No anticholinergic burden (no dry mouth, constipation, or cognitive concerns) 3, 4
- Safer in elderly and frail patients 2, 9
- Can be used in patients with narrow-angle glaucoma or gastric emptying issues 3
Combination Therapy Evidence:
The SYNERGY and BESIDE trials established that combining solifenacin (5 mg) with mirabegron (25 or 50 mg) provides superior efficacy compared to monotherapy without significantly increasing adverse effects 1. This combination approach is recommended for patients refractory to monotherapy 1, 3.
Important Clinical Considerations
Beta-3 agonists should be considered as first-line pharmacologic therapy before antimuscarinics in patients at higher risk for anticholinergic adverse events, including the elderly, those with cognitive concerns, and patients with multiple comorbidities 3, 4. The evidence consistently supports their use with adherence rates of 53.8% at 12 months, which is superior to antimuscarinics 10.